Vaccine For Chikungunya
What Is Chikungunya
It is viruses of the Togaviridae family, such as the chikungunya virus (CHIKV), that cause the disease, which is carried by Aide’s mosquitoes and manifests itself as an itchy rash. The Chikungunya virus, which affects between one-third and three-quarters of the population in areas where the virus is circulating, is typically responsible for a large number of sudden big outbreaks with high attack rates. In the United States, because there are presently no prophylactic vaccines or effective treatments available, chikungunya is considered to be a major public health threat. There were more than 3 million documented cases in the Americas as of September 2020[4, according to the World Health Organization, and the economic burden is considered to be severe. Medical and economic burdens are expected to rise as the CHIKV primary mosquito vectors move regionally, according to current projections. If a mosquito bite causes an infection, symptomatic sickness develops in 72-92 percent of humans four to seven days after the bite, depending on the strain of the infection. However, despite the low fatality rate associated with CHIKV, the morbidity rate is exceedingly significant. One or more of the clinical signs and symptoms of arthralgia include a high fever with an abrupt onset as well as painful joint and muscular pain, nausea, rash, and chronic arthralgia. Areas where chikungunya disease mosquitoes are now endemic, such as regions of Africa and Southeast Asia, as well as the Americas and the Caribbean, are considered high-risk for infection with the virus.
The chikungunya virus, which has spread to more than 120 countries, is being targeted with the development of a viral-attenuated, single-dose vaccine candidate called VLA1553. Previously existent portions of the genome of the chikungunya virus were removed in order to develop this virus.
If VLA1553 is approved, Valneva aims to commercialize it, since it would be a welcome addition to the company’s already-existing commercial vaccine portfolio. As a result, the business wants to make use of its existing production and commercial skills in order to get the vaccine to market as quickly as possible. It is predicted that by 2032, the global market for vaccines against chikungunya will reach more than $500 million per year, according to industry projections.
A contract with the Brazilian Institute of Butantan to develop, manufacture, and market VLA1553 was signed in January 2021, with the goal of making it more affordable to Low and Middle Income Countries (LMIC). This collaboration will make VLA1553 more readily available in low- and middle-income countries. Following the signing of an agreement between CEPI and Valneva in July 2019, the collaboration will fall under the umbrella of the European Union’s Horizon 2020 program me, which will provide funding of up to $23.4 million in support of the project.
About Phase 3 Trial Vla1553-301
The VLA1553-301 Phase 3 trial is slated to commence in September 2020 and is expected to last for two years. A phase 3 trial with 4,115 participants who are 18 years or older and is being conducted prospectively, double-blinded, at different sites, and with randomization is being conducted in this study. In this investigation, participants received a single intramuscular immunization with lyophilized VLA1553 or received a placebo. Among the key objectives of the study was to determine the immunogenicity and safety of VLA1553 in healthy volunteers one month following a single immunization with the vaccine. It is possible to find a detailed explanation of the trial’s design, eligibility criteria, and investigator sites by visiting the ClinicalTrials.gov website (Identifier: NCT04546724).
About Valneva SE
Valneva is a specialty vaccine company based in San Diego, California, that specializes in the discovery, manufacture, and marketing of preventive vaccines for infectious diseases with a high unmet medical need. Valneva was founded in 2000 by Dr. David S. Rosenberg. A specialized and targeted approach is taken by the Company while conducting vaccine research, and it then utilises its considerable expertise of vaccine technology to develop preventative immunizations that treat these diseases on a wide scale, as described above. Valneva has been successful in commercializing two vaccines while also progressing a significant number of vaccine candidates through the clinical trial phase, including vaccines for Lyme disease, the chikungunya virus, and COVID-19.